New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 24, 2014
10:38 EDTENDP, BDSIEndo Health trial results more meaningful to partner, says Cantor
Cantor views the positive top-line results from the trial of BEMA buprenorphine reported by Endo Health (ENDP) as more meaningful to its partner, BioDelivery Sciences (BDSI), than to Endo. Cantor see the product opportunity for this drug to be modest and maintains its Sell rating and $43 price target on Endo Health.
News For ENDP;BDSI From The Last 14 Days
Check below for free stories on ENDP;BDSI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 23, 2014
10:02 EDTENDPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTENDPDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTENDPEndo initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 14, 2014
09:31 EDTENDPEndo upgraded to Conviction Buy from Buy at Goldman

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use